Pay in 4 interest-free payments of $6.62 Learn more
Ships within 48 hours Β· Estimated delivery Aug 7 - Aug 12
(8) If constipation is the problem, a careful increase can help
You accidentally added too much water
If you get chronic headaches from toxins and oxidative stress, glutathione a potent detoxifier could alleviate your headaches by eliminating harmful substances
Integrated vs
Financial Dominance & Operating Leverage Q3 2025 Financial Highlights Revenue: $17.6B (+54% YoY) Non-GAAP EPS: $7.02 (+495% YoY) Gross Margin: 83.6% (+1.4 pts) Operating Cash: Strong (Record levels) Full-Year 2025 Guidance (Raised) Revenue: $63.0-63.5B (up from $60-62B) Non-GAAP EPS: $23.00-23.70 (up from $21.75-23.00) Profitability Metrics Return on Equity (ROE): ~74-88% (exceptional capital efficiency) Gross Margin: 83.6% (among highest in pharma) R&D Investment: $3.47B in Q3 (+27% YoY) fueling future growth These metrics place Lilly among the most efficient, profitable companies in the S&P 500
US$ 25.93
US$ 29.37
US$ 26.82
US$ 20.40
US$ 28.44
US$ 26.41
